Research Progress in Prodrugs of Acyclic Nucleoside Phosphonates Antiviral Agents

doi:10.6023/cjoc201808018

Chin. J. Org. Chem. ›› 2019, Vol. 39 ›› Issue (4): 974-981.DOI: 10.6023/cjoc201808018 Previous Articles Next Articles

Reviews

开环膦酸核苷类抗病毒药物前药的研究进展

高梦远^a, 刘洪涛^b, 连玉菲^b, 高欣丰^a, 耿云鹤^a, 李文燕^a

a 河北师范大学化学与材料科学学院石家庄 050024;
b 河北省人民医院药学部石家庄 050051

收稿日期:2018-08-16 修回日期:2018-10-15 发布日期:2018-11-30
通讯作者: 李文燕 E-mail:liyan8512@163.com
基金资助:
河北省自然科学基金（No.H2018307055）、河北师范大学技术创新基金（No.L2017K06）资助项目.

Research Progress in Prodrugs of Acyclic Nucleoside Phosphonates Antiviral Agents

Gao Mengyuana^a, Liu Hongtaob^b, Lian Yufeib^b, Gao Xinfenga^a, Geng Yunhea^a, Li Wenyan^a

a Hebei Normal University, College of Chemistry & Material Science, Shijiazhuang 050024;
b Department of Pharmacy, Hebei General Hospital, Shijiazhuang 050051

Received:2018-08-16 Revised:2018-10-15 Published:2018-11-30
Contact: 10.6023/cjoc201808018 E-mail:liyan8512@163.com
Supported by:
Project supported by the Natural Science Foundation of Hebei Province (No.H2018307055) and the Technology Innovation Foundation of Hebei Normal University (No.L2017K06).

More and more attention has been focused on acyclic nucleoside phosphonates (ANPs) antiviral agents which were wildly used in clinical therapy. However, poor oral bioavailability and high toxicity directly related to the phosphonate charge were serious and unnegligible especially for the treatment of chronic diseases such as hepatitis B virus (HBV) and human immunodeficiency virus (HIV). Preparing appropriate forms of prodrug could enhance the oral bioavailability and reduce the toxicity because of the smooth absorption of prodrugs and the release of active drug only at the target. This review summarizes some recent progress in prodrugs of ANPs antiviral agents based on the structures of tenofovir, adefovir and cidofovir.

Key words: acyclic nucleoside phosphonates (ANPs), antiviral agents, prodrug

Cite this article

Gao Mengyuana, Liu Hongtaob, Lian Yufeib, Gao Xinfenga, Geng Yunhea, Li Wenyan. Research Progress in Prodrugs of Acyclic Nucleoside Phosphonates Antiviral Agents[J]. Chin. J. Org. Chem., 2019, 39(4): 974-981.

Export EndNote|Reference Manager|ProCite|BibTeX|RefWorks

share this article

References

[1] (a) De Clercq, E. Biochem. Pharmacol. 2013, 86, 711.
(b) De Clercq, E. Adv. Pharmacol. 2013, 67, 293.
(c) De Clercq, E.; Holy, A. Nat. Rev. Drug Discovery 2005, 4, 928.
(d) Liu, K.; Xie, L. Acta Pharm. Sin. 2006, 41, 689(in Chinese).(刘琨, 谢蓝, 药学学报, 2006, 41, 689.)
[2] (a) De Clercq, E. Expert. Rev. Anti-Infect. Ther. 2003, 1, 21.
(b) De Clercq, E. Biochem. Pharmacol. 2011, 82, 99.
(c) De Clercq, E. Med. Res. Rev. 2013, 33, 1278.
[3] Peng, Y. M.; Yu, W. Q.; Li, E. T.; Kang, J. F.; Wang, Y. F.; Yang, Q. H.; Liu, B. J.; Zhang, J. M.; Li, L. Y.; Wu, J.; Jiang, J. H.; Wang, Q. D.; Chang, J. B. J. Med. Chem. 2016, 59, 3661.
[4] Pertusati, F.; Serpi, M.; McGuigan, C. Antivir. Chem. Chemother. 2012, 22, 181.
[5] De Clercq, E. Clin. Microbiol. Rev. 2003, 16, 569.
[6] De Clercq, E. Antiviral Res. 2007, 75, 1.
[7] (a) Krecmerova, M. Mini-Rev. Med. Chem. 2017, 17, 818.
(b) Hecker, S. J.; Erion, M. D. J. Med. Chem. 2008, 51, 2328.
(c) Wiemer, A. J.; Wiemer, D. F. Top. Curr. Chem. 2015, 360, 115.
(d) Xie, M. S.; Chen, Y. G.; Wu, X. X.; Qu, G. R.; Guo, H. M. Org. Lett. 2018, 20, 1212.
[8] (a) Yang, K. H.; Wang, J. T.; Li, Q. B.; Xu, W. F. Food Drug 2018, 10, 60(in Chinese).(杨康辉, 王举涛, 李乾斌, 徐文方, 食品与药品, 2018, 10, 60.)
(b) Wang, S. X.; Duan, H. D.; Meng, X.; Qin, D. W.; Wang, L. Z.; Li, X. M. J. Beijing Union Univ. (Nat. Sci.) 2010, 24, 29(in Chinese).(王世潇, 段洪东, 孟霞, 秦大伟, 王利振, 李晓萌, 北京联合大学学报(自然科学版), 2010, 24, 29.)
(c) Li, W. B.; Dong, F. H.; Sun, C. J. Prog. Pharm. Sci. 2012, 36, 300(in Chinese).(李文保, 董芳华, 孙昌俊, 药学进展, 2012, 36, 300.)
[9] Kearney, B. P.; Flaherty, J. F.; Shah, J. Clin. Pharmacokinet. 2004, 43, 595.
[10] Nelson, M. R.; Katlama, C.; Montaner, J. S.; Cooper, D. A.; Gazzard, B.; Clotet, B.; Lazzari, A.; Schewe, K.; Lange, J.; Wyatt, C. AIDS 2007, 21, 1273.
[11] Barditch-Crovo, P.; Deeks, S. G.; Collier, A.; Safrin, S.; Coakley, D. F.; Miller, M.; Kearney, B. P.; Coleman, R. L.; Lamy, P. D.; Kahn, J. O. Antimicrob. Agents Chemother. 2001, 45, 2733.
[12] Ray, A. S.; Fordyce, M. W.; Hitchcock, M. J. M. Antiviral Res. 2016, 125, 63.
[13] Ruane, P. J.; DeJesus, E.; Berger, D.; Markowitz, M.; Bredeek, U. F.; Callebaut, C.; Zhong, L.; Ramanathan, S.; Rhee, M. S.; Fordyce, M. W. J. Acquired Immune Defic. Syndr. 2013, 63, 449.
[14] (a) Sax, P. E.; Zolopa, A.; Brar, I.; Elion, R.; Ortiz, R.; Post, F.; Wang, H.; Callebaut, C.; Martin, H.; Fordyce, M. W. J. J. Acquired Immune Defic. Syndr. 2014, 67, 52.
(b) Zhang, X. Q. Acta. Pharm. Sin. 2015, 50, 509(in Chinese).(张兴权, 药学学报, 2015, 50, 509.)
[15] Painter, G. R.; Almond, M. R.; Trost, L. C.; Lampert, B. M.; Neyts, J.; De Clercq, E.; Korba, B. E.; Aldern, K. A.; Beadle, J. R.; Hostetler, K. Y. Antimicrob. Agents Chemother. 2007, 51, 3505.
[16] Lanier, E. R.; Lampert, B.; Trost, L.; Painter, G.; Almond, M. Antiviral Ther. 2008, 13, A6.
[17] Tanwandee, T.; Chatsiricharoenkul, S.; Thongsawat, S.; Sukeepaisarnjaroen, W.; Tangkijvanich, P.; Komolmit, P.; Avihingsanon, A.; Piratvisuth, T.; Sunthi, P.; Mahasanprasert, T. J. Hepatol. 2017, 66, S24.
[18] Chatsiricharoekul, S.; Jutasompakorn, P.; Niyomnaitham, S.; Matkovits, T.; Conover, M.; Cobb, J.; Greytok, J.; Sullivan-Bolyai, J. Clin. Pharmacol. Ther. 2017, 101, S48.
[19] Giesler, K. E.; Marengo, J.; Liotta, D. C. J. Med. Chem. 2016, 59, 7097.
[20] Giesler, K. E.; Liotta, D. C. J. Med. Chem. 2016, 59, 10244.
[21] Marcellin, P.; Chang, T.-T.; Lim, S. G.; Tong, M. J.; Sievert, W.; Shiffman, M. L.; Jeffers, L.; Goodman, Z.; Wulfsohn, M. S.; Xiong, S. N. Engl. J. Med. 2003, 348, 808.
[22] Marcellin, P.; Chang, T.-T.; Lim, S. G. L.; Sievert, W.; Tong, M.; Arterburn, S.; Borroto-Esoda, K.; Frederick, D.; Rousseau, F. Hepatology 2008, 48, 750.
[23] Ingiliz, P.; Valantin, M.-A.; Thibault, V.; Duvivier, C.; Dominguez, S.; Katlama, C.; Poynard, T.; Benhamou, Y. Antivir. Ther. 2008, 13, 895.
[24] Reddy, K. R.; Matelich, M. C.; Ugarkar, B. G.; Gomez-Galeno, J. E.; DaRe, J.; Ollis, K.; Sun, Z.; Craigo, W.; Colby, T. J.; Fujitaki, J. M. J. Med. Chem. 2008, 51, 666.
[25] Lin, C. C.; Fang, C.; Benetton, S.; Xu, G. F.; Yeh, U. T. Antimicrob. Agents Chemother. 2006, 50, 2926.
[26] Ding, Y.; Zhang, H.; Li, X.; Li, C.; Chen, G.; Chen, H.; Wu, M.; Niu, J. Hepatol. Int. 2017, 11, 390.
[27] Fu, X.; Jiang, S.; Li, C.; Xin, J.; Yang, Y.; Ji, R. Bioorg. Med. Chem. Lett. 2007, 17, 465.
[28] Fu, X. Z.; Wang, Y. L.; Lan, Y. Y.; Wang, A. M.; Ou, Y.; Luo, C.; Li, Y. Acta Pharm. Sin. 2010, 45, 1017(in Chinese).(傅晓钟, 王永林, 兰燕宇, 王爱民, 欧瑜, 罗春, 李燕, 药学学报, 2010, 45, 1017.)
[29] Fu, X.-Z.; Ou, Y.; Pei, J.-Y.; Liu, Y.; Li, J.; Zhou, W.; Lan, Y.-Y.; Wang, A.-M.; Wang, Y.-L. Eur. J. Med. Chem. 2012, 49, 211.
[30] Magee, W. C.; Evans, D. H. Antiviral Res. 2012, 96, 169.
[31] (a) De Clercq, E. Trends Pharmacol. Sci. 2002, 23, 456.
(b) Andrei, G.; Topalis, D.; De Schutter, T.; Snoeck, R. Antiviral Res. 2015, 114, 21.
[32] Cundy, K. C.; Bidgood, A. M.; Lynch, G.; Shaw, J. P.; Griffin, L.; Lee, W. A. Drug. Metab. Dispos. 1996, 24, 745.
[33] (a) Beadle, J. R.; Hartline, C.; Aldern, K. A.; Rodriguez, N.; Harden, E.; Kern, E. R.; Hostetler, K. Y. Antimicrob. Agents Chemother. 2002, 46, 2381.
(b) Hostetler, K. Y. Viruses 2010, 2, 2213.
[34] Marty, F. M.; Winston, D. J.; Rowley, S. D.; Vance, E.; Papanicolaou, G. A.; Mullane, K. M.; Brundage, T. M.; Robertson, A. T.; Godkin, S.; Mommeja-Marin, H. N. Engl. J. Med. 2013, 369, 1227.
[35] Marty, F. M.; Winston, D. J.; Chemaly, R. F.; Boeckh, M. J.; Mullane, K. M.; Shore, T. B.; Papanicolaou, G. A.; Morrison, M. E.; Brundage, T. M.; Mommeja-Marin, H. Biol. Blood Marrow. Transplant. 2016, 22, S23.
[36] (a) Florescu, D.; Grimley, M.; Papanicolaou, G.; Prasad, V.; Vainorius, E.; Chittick, G.; Brundage, T.; Nichols, G. Am. J. Transplant. 2018, 18, S360.
(b) Chittick, G.; Morrison, M.; Brundage, T.; Nichols, W. G. Antivir. Res. 2017, 143, 269.
[37] Dunning, J.; Kennedy, S. B.; Antierens, A.; Whitehead, J.; Ciglenecki, I.; Carson, G.; Kanapathipillai, R.; Castle, L.; Howell-Jones, R.; Pardinaz-Solis, R. PLoS One 2016, 11, e0162199.
[38] Lampertico, P. Gut 2014, 63, 869.
[39] Mak, L.-Y.; Seto, W.-K.; Lai, C.-L.; Yuen, M.-F. Expert Opin. Drug Metab. Toxicol. 2018, 14, 101.
[40] Ahn, S. H.; Kim, W.; Jung, Y. K.; Yang, J. M.; Jang, J. Y.; Kweon, Y. O.; Cho, Y. K.; Kim, Y. J.; Hong, G. Y.; Kim, D. J. J. Hepatol. 2017, 66, S88.
[41] Lai, C.-L.; Ahn, S. H.; Lee, K. S.; Um, S. H.; Cho, M.; Yoon, S. K.; Lee, J.-W.; Park, N. H.; Kweon, Y.-O.; Sohn, J. H. Gut 2014, 63, 996.
[42] Yuen, M.-F.; Ahn, S. H.; Lee, K. S.; Um, S. H.; Cho, M.; Yoon, S. K.; Lee, J.-W.; Park, N. H.; Kweon, Y. O.; Sohn, J. H. Hepatology 2013, 58, 693A.
[43] Yuen, M.-F.; Ahn, S. H.; Lee, K. S.; Um, S. H.; Cho, M.; Yoon, S. K.; Lee, J.-W.; Park, N. H.; Kweon, Y.-O.; Sohn, J. H. J. Hepatol. 2015, 62, 526.
[44] Baszczynski, O. Janeba, Z. Med. Res. Rev. 2013, 33, 1304.
[45] Luo, M.; Groaz, E.; Andrei, G.; Snoeck, R.; Kalkeri, R.; Ptak, R. G.; Hartman, T.; Buckheit, R. W., Jr.; Schols, D.; De Jonghe, S. J. Med. Chem. 2017, 60, 6220.
[46] Holy, A.; Gunter, J.; Dvorakova, H.; Masojidkova, M.; Andrei, G.; Snoeck, R.; Balzarini, J.; De Clercq, E. J. Med. Chem. 1999, 42, 2064.
[47] Jansa, P.; Baszczyňski, O.; Dracínský, M.; Votruba, I.; Zídek, Z.; Bahador, G.; Stepan, G.; Cihlar, T.; Mackman, R.; Holý, A; Jansa, Z. Eur. J. Med. Chem. 2011, 46, 3748.

开环膦酸核苷类抗病毒药物前药的研究进展

Research Progress in Prodrugs of Acyclic Nucleoside Phosphonates Antiviral Agents

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 6

Recommended Articles

Metrics

Comments

[1]	Zhang Yunxi, Gao Huchuan, Zhang Chenrui, Sun Maosheng, Chen Yangjie, Zeng Lisheng, Huang Lan, Chen Peng, Huang Qianming, Pu Xiang. Advances in the Study of Structural Modification of Aspirin and Their Biological Activities [J]. Chinese Journal of Organic Chemistry, 2020, 40(2): 300-326.
[2]	Liu Yichen, Cheng Jiefei, Hong Ran. Asymmetric Synthesis of Prodrug Nucleotides (ProTides): Construction of the P-Stereogenic Centers [J]. Chinese Journal of Organic Chemistry, 2020, 40(10): 3237-3248.
[3]	Nie Biao, Jin Chuanfei, Zhong Wenhe, Ren Qingyun, Zhang Yingjun, Zhang Ji. Application and Recent Progress of Phosphoramidate Prodrugs Strategies and ProTide Technology in Drug Discovery [J]. Chin. J. Org. Chem., 2017, 37(11): 2818-2840.
[4]	Tu Yongyuan, Xu Xianxiang, Qiu Fei. Research Progress in the Prodrugs of Curcumin [J]. Chin. J. Org. Chem., 2012, 32(05): 852-859.
[5]	XU Hao,HUANG Wen-Long*,ZHANG Hui-Bing,ZHOU Jin-Pei. Synthesis of the Derivatives of Andrographolide for NO Donor [J]. Chin. J. Org. Chem., 2005, 25(11): 1386-1391.
[6]	Sun Xun;Hu Changqi;Huang Xiaodong;Dong Jichang. Mannich Reaction of Baicalein [J]. Chin. J. Org. Chem., 2003, 23(1): 81-85.